ASTEC V1.3 Code Assessment on the STORM Aerosols Mechanical REsuspension Test (A Fission Product Transport Study)

The European severe accident analysis code ASTEC is assessed on the most representative STORM tests. Two aerosol resuspension modules are used to calculate the resuspended fraction of aerosols deposited in the primary circuit model of STORM facility. It was concluded thta concerning the final mass fraction and mainly the kinetics of aerosol resuspension in turbulent pipe flow conditions there is a need for further code assesment and for improvement of resuspension models implemented in the current version of SOP"HAEROS/ASTEC V1.3 code. This is under way in the Source Term area of the SARNET project.JRC.F.4-Nuclear design safet

Risk Informed Support of Decision Making in Nuclear Power Plant Emergency Zoning - Generic Framework towards Harmonising NPP Emergency Planning Practices

The report provides a systematic overview of the essential aspects of risk informed support of decision making (RIDM) in nuclear power plant (NPP) emergency zoning (EZ) as a contribution to harmonising strategic practices in the area. Owing to the state-of-the-art understanding and increased characterisation of NPP severe accidents, overall management of them should be analysed as an integrated complex process. The interrelationship of NPP emergency operating procedures, safety and risk assessments, severe accident management guidelines, and emergency off-site actions should be planned and organised to minimize the consequences of such accidents. A deterministic approach, coupled with both probabilistic safety assessment (PSA) technology and PSA results can play significant role in the development of relevant nuclear utility, regulatory and all stakeholders policies. The report describes the background, objectives and current state of a corresponding activity within JRC-IE's Analysis and Management of Nuclear Accidents (AMA) Action on probabilistic safety / risk assessment methodologies and practices for RIDM approach applied to NPP EZ. The approach is interdisciplinary, based on integration of PSA technology, severe accident phenomenology, and radiological protection.JRC.F.4-Nuclear design safet

Oxidation and Release of Ruthenium from White Inclusions

In this paper the laboratory test results on oxidation and release of ruthenium as a fission product element are summarised. The ruthenium appears in the nuclear fuel pellets of pressurized water reactors as one of the fission product elements during burnup. In case of severe accident when the air can contact the degraded hot fuel, the ruthenium oxidises and its gaseous oxides, especially the RuO4, release rapidly from the pellets to the environment. Because of high radio- and chemotoxicity of ruthenium tetra-oxide further experimental study of oxidation and release is essential. It is well known that ruthenium in the irradiated fuel UO2 fuel appears in small metallic alloy precipitations together with fission product elements as Mo, Rh, Pd and Tc. The precipitations are seen in the metallographic pictures as white inclusions. This separate effect study focused on the differences in the release rate of gaseous ruthenium oxides when pure ruthenium or Mo-Ru-Rh-Pd metallic alloy is present in the simulated nuclear fuel. The oxidation and release were studied at constant reaction temperatures of 1000 or 1100 Celsius. The tests showed that during high-temperature oxidation of the Mo-Ru-Rh-Pd alloy in air flow the release rate of gaseous ruthenium oxides is reduced to 60-80% compared to the value measured in case of oxidation of pure metallic ruthenium powder in the same thermal-hydraulic conditions. Furthermore, if additional elements and chemical compounds representing other fission products were added in the alloy, a time delay of 30 to 60 min appeared in the release of gaseous ruthenium to the room-temperature environment. One of the main results was that in the outlet air flow reaching the environment the partial pressure of RuO4 was far above what could be expected for room-temperature equilibrium conditions. It was pointed out that the highly volatile RuO4 can decompose in solid, non-volatile RuO2 and O2. The X-ray fluorescence analysis results showed that some ruthenium compounds deposited on the colder circuit walls of the test facility. This suggests RuO4 is not fully airstable, i.e., its stability in air can be limited in time.JRC.F.4-Nuclear design safet

Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island.

BACKGROUND: The septin 9 gene (SEPT9) codes for a GTP-binding protein associated with filamentous structures and cytoskeleton formation. SEPT9 plays a role in multiple cancers as either an oncogene or a tumor suppressor gene. Regulation of SEPT9 expression is complex and not well understood; however, hypermethylation of the gene was recently introduced as a biomarker for early detection of colorectal cancer (CRC) and has been linked to cancer of the breast and of the head and neck. Because the DNA methylation landscape of different regions of SEPT9 is poorly understood in cancer, we analyzed the methylation patterns of this gene in distinct cell populations from normal and diseased colon mucosa. METHODS: Laser capture microdissection was performed to obtain homogeneous populations of epithelial and stromal cells from normal, adenomatous, and tumorous colon mucosa. Microdissected samples were analyzed using direct bisulfite sequencing to determine the DNA methylation status of eight regions within and near the SEPT9 gene. Septin-9 protein expression was assessed using immunohistochemistry (IHC). RESULTS: Regions analyzed in SEPT9 were unmethylated in normal tissue except for a methylation boundary detected downstream of the largest CpG island. In adenoma and tumor tissues, epithelial cells displayed markedly increased DNA methylation levels (>80%, p <0.0001) in only one of the CpG islands investigated. SEPT9 methylation in stromal cells increased in adenomatous and tumor tissues (<=50%, p <0.0001); however, methylation did not increase in stromal cells of normal tissue close to the tumor. IHC data indicated a significant decrease (p <0.01) in Septin-9 protein levels in epithelial cells derived from adenoma and tumor tissues; Septin-9 protein levels in stromal cells were low in all tissues. CONCLUSIONS: Hypermethylation of SEPT9 in adenoma and CRC specimens is confined to one of several CpG islands of this gene. Tumor-associated aberrant methylation originates in epithelial cells; stromal cells appear to acquire hypermethylation subsequent to epithelial cells, possibly through field effects. The region in SEPT9 with disease-related hypermethylation also contains the CpGs targeted by a novel blood-based screening test (Epi proColon(R)), providing further support for the clinical relevance of this biomarker

Final Interpretation Report of the PHEBUS test FPT0: Bundle Aspects

In this paper, the actual status of understanding of the dominant bundle degradation processes is presented. Here, mainly the results reported in the last years in the Bundle Interpretation Circles organised by JRC/IE and IRSN (Institut de Radioprotection et de Surete Nucleaire, Cadarache) are summarised. For the extensive and detailed computational analyses the commonly used severe accident codes such as ICARE, MELCOR, SCDAP/RELAP and ATHLET-CD are used. For the analysis of fission product release from the FPT0 bundle, specific codes such as SVECHA and XMPR were used as well.JRC.F.4-Nuclear design safet

Pilot analysis of the usefulness of mortality risk score systems at resuscitated patients

Introduction: Sudden cardiac death is one of the most significant cardiovascular causes of death worldwide. Although there have been immense methodological and technical advances in the field of cardiopulmonary resuscitation and following intensive care in the last decade, currently there are only a few validated risk-stratification scoring systems for the quick and reliable estimation of the mortality risk of these patients at the time of admission to the intensive care unit. Objective: Our aim was to correlate the mortality prediction risk points calculated by CardShock Risk Score (CSRS) and modified (m) CSRS based on the admission data of the post-cardiac arrest syndrome (PCAS) patients. Methods: The medical records of 172 out-of-hospital resuscitated cardiac arrest patients, who were admitted at the Heart and Vascular Centre of Semmelweis University, were screened retrospectively. Out of the 172 selected patients, 123 were eligible for inclusion to calculate CSRS and mCSRS. Based on CSRS score, we generated three different groups of patients, with scores 1 to 3, 4 to 6, and 7+, respectively. Mortality data of the groups were compared by log-rank test. Results: Mean age of the patients was 63.6 years (69% male), the cause of sudden cardiac death was acut coronary syndrome in 80% of the cases. The early and late mortality was predicted by neurological status, serum lactate level, renal function, initial rhythm, and the need of catecholamines. Using mCSRS, a significant survival difference was proven in between the groups "1-3" vs "4-6" (p Conclusion: Compared to the CSRS, the mCSRS expanded with the 2 additional weighting points differentiates more specifically the low-moderate and high survival groups in the PCAS patient population treated in our institute.Peer reviewe

The Drug Candidate BGP-15 Delays the Onset of Diastolic Dysfunction in the Goto-Kakizaki Rat Model of Diabetic Cardiomyopathy

L

Uncommon presentation of a rare tumour - incidental finding in an asymptomatic patient: case report and comprehensive review of the literature on intrapericardial solitary fibrous tumours

BACKGROUND: A solitary fibrous tumour is a rare, mainly benign spindle cell mesenchymal tumour most commonly originating from the pleura. An intrapericardial location of a solitary fibrous tumour is extremely unusual. We present a case of an asymptomatic patient with a slow-growing massive benign cardiac solitary fibrous tumour. CASE PRESENTATION: A 37-year-old asymptomatic female patient was referred to our hospital with an enlarged cardiac silhouette found on her screening chest X-ray. The echocardiographic examination revealed pericardial effusion and an inhomogeneous mobile mass located in the pericardial sac around the left ventricle. Cardiac magnetic resonance (MRI) examination showed an intrapericardial, semilunar-shaped mass attached to the pulmonary trunk with an intermediate signal intensity on proton density-weighted images and high signal intensity on T2-weighted spectral fat saturation inversion recovery images. First-pass perfusion and early and late gadolinium-enhanced images showed a vascularized mass with septated, patchy, inhomogeneous late enhancement. Coronary computed tomography angiography revealed no invasion of the coronaries. Based on the retrospectively analysed screening chest X-rays, the mass had started to form at least 7 years earlier. Complete resection of the tumour with partial resection of the pulmonary trunk was performed. Histological evaluation of the septated, cystic mass revealed tumour cells forming an irregular patternless pattern; immunohistochemically, the cells tested positive for vimentin, CD34, CD99 and STAT6 but negative for keratin (AE1-AE3), CD31 and S100. Thus, the diagnosis of an intrapericardial solitary fibrous tumour was established. There has been no recurrence for 3 years based on the regular MRI follow-up. CONCLUSION: Intrapericardial SFTs, showing slow growth dynamics, can present with massive extent even in completely asymptomatic patients. MRI is exceedingly useful for characterizing intrapericardial masses, allowing precise surgical planning, and is reliable for long-term follow up

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D